Novo Nordisk A/S (NVO) Earnings History
Annual and quarterly earnings data from 1990 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 81.0% | 41.4% | 33.1% |
| 2024 | 84.7% | 44.2% | 34.8% |
| 2023 | 84.6% | 44.2% | 36.0% |
| 2022 | 83.9% | 42.3% | 31.4% |
| 2021 | 83.2% | 41.7% | 33.9% |
Download Data
Export NVO earnings history in CSV or JSON format
Free sign-in required to download data
Novo Nordisk A/S (NVO) Earnings Overview
As of March 2, 2026, Novo Nordisk A/S (NVO) reported trailing twelve-month net income of $98.50B, reflecting +0.0% year-over-year growth. The company earned $22.15 per diluted share over the past four quarters, with a net profit margin of 0.3%.
Looking at the long-term picture, NVO's 5-year EPS compound annual growth rate (CAGR) stands at +20.6%, indicating exceptional earnings growth. The company achieved its highest annual net income of $100.99B in fiscal 2024.
Novo Nordisk A/S maintains positive profitability with a gross margin of 0.8%, operating margin of 0.4%, and net margin of 0.3%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including ABBV ($2.39B net income, 0.1% margin), AMGN ($7.71B net income, 0.2% margin), GILD ($8.51B net income, 0.0% margin), NVO has outperformed on profitability metrics. Compare NVO vs ABBV →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
36 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $98.50B | -2.5% | $123.04B | $23.03 | 33.1% | 41.4% |
| 2024 | $100.99B | +20.7% | $128.34B | $22.63 | 34.8% | 44.2% |
| 2023 | $83.68B | +50.7% | $102.57B | $18.62 | 36.0% | 44.2% |
| 2022 | $55.52B | +16.3% | $74.81B | $12.22 | 31.4% | 42.3% |
| 2021 | $47.76B | +13.3% | $58.64B | $10.37 | 33.9% | 41.7% |
| 2020 | $42.14B | +8.2% | $54.13B | $9.01 | 33.2% | 42.6% |
| 2019 | $38.95B | +0.8% | $52.48B | $8.19 | 31.9% | 43.0% |
| 2018 | $38.63B | +1.3% | $47.25B | $7.97 | 34.5% | 42.2% |
| 2017 | $38.13B | +0.5% | $48.97B | $7.70 | 34.1% | 43.8% |
| 2016 | $37.92B | +8.8% | $48.43B | $7.48 | 33.9% | 43.3% |
See NVO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NVO Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare NVO vs AGIO
See how NVO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is NVO growing earnings?
NVO TTM EPS: $22.15. Net income: $98.5B. Earnings growth: +0.0%.
What are NVO's profit margins?
Novo Nordisk A/S net margin is +0.3%, with operating margin at +0.4%. Below-average margins reflect competitive or cost pressures.
How consistent are NVO's earnings?
NVO earnings data spans 1990-2025. The current earnings trend is +0.0% YoY. Historical data enables comparison across business cycles.